(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.79%) $83.19
(-1.16%) $1.619
(-0.32%) $2 339.70
(-0.04%) $27.53
(0.49%) $926.60
(-0.18%) $0.933
(-0.18%) $11.01
(-0.26%) $0.798
(0.00%) $92.17
2 days till quarter result
(bmo 2024-05-01)
Expected move: +/- 6.71%
@ $64.15
发出时间: 27 Apr 2024 @ 01:48
回报率: -0.14%
上一信号: Apr 26 - 03:50
上一信号:
回报率: 2.40 %
Live Chart Being Loaded With Signals
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide...
Stats | |
---|---|
今日成交量 | 946 213 |
平均成交量 | 1.09M |
市值 | 10.07B |
EPS | $0 ( 2024-02-01 ) |
下一个收益日期 | ( $0.460 ) 2024-05-01 |
Last Dividend | $0.0800 ( 2023-11-09 ) |
Next Dividend | $0 ( N/A ) |
P/E | 46.09 |
ATR14 | $1.869 (2.91%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-03 | Bohnen Shane | Sell | 2 259 | Restricted Stock Units |
2024-04-03 | Bohnen Shane | Buy | 2 259 | Common Stock |
2024-04-03 | Bohnen Shane | Sell | 747 | Common Stock |
2024-03-07 | Nusse Roeland | Sell | 10 400 | Common Stock |
2024-02-01 | Geist William | Sell | 1 111 | Common Stock |
INSIDER POWER |
---|
3.67 |
Last 99 transactions |
Buy: 1 979 464 | Sell: 2 067 622 |
音量 相关性
Bio-Techne Corp 相关性 - 货币/商品
Bio-Techne Corp 财务报表
Annual | 2023 |
营收: | $1.14B |
毛利润: | $769.82M (67.72 %) |
EPS: | $1.810 |
FY | 2023 |
营收: | $1.14B |
毛利润: | $769.82M (67.72 %) |
EPS: | $1.810 |
FY | 2022 |
营收: | $1.11B |
毛利润: | $756.50M (68.42 %) |
EPS: | $1.730 |
FY | 2021 |
营收: | $931.03M |
毛利润: | $632.85M (67.97 %) |
EPS: | $0.867 |
Financial Reports:
No articles found.
Bio-Techne Corp Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.0800 (N/A) |
$0.0800 (N/A) |
$0.0800 (N/A) |
$0.0800 (N/A) |
$0.0800 (N/A) |
$0.0800 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.0625 | 2008-10-30 |
Last Dividend | $0.0800 | 2023-11-09 |
Next Dividend | $0 | N/A |
Payout Date | 2023-11-24 | |
Next Payout Date | N/A | |
# dividends | 61 | -- |
Total Paid Out | $4.63 | -- |
Avg. Dividend % Per Year | 0.25% | -- |
Score | 4.89 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 6.04 | |
Div. Directional Score | 8.94 | -- |
Year | Amount | Yield |
---|---|---|
2008 | $0.0625 | 0.37% |
2009 | $0.253 | 1.57% |
2010 | $0.263 | 1.53% |
2011 | $0.273 | 1.64% |
2012 | $0.285 | 1.66% |
2013 | $0.303 | 1.75% |
2014 | $0.313 | 1.33% |
2015 | $0.320 | 1.40% |
2016 | $0.320 | 1.45% |
2017 | $0.320 | 1.25% |
2018 | $0.320 | 0.97% |
2019 | $0.320 | 0.90% |
2020 | $0.320 | 0.58% |
2021 | $0.320 | 0.41% |
2022 | $0.320 | 0.26% |
2023 | $0.320 | 0.39% |
2024 | $0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.196 | 1.500 | 6.08 | 9.13 | [0 - 0.5] |
returnOnAssetsTTM | 0.0821 | 1.200 | 7.26 | 8.72 | [0 - 0.3] |
returnOnEquityTTM | 0.115 | 1.500 | 9.84 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.225 | -1.000 | 7.75 | -7.75 | [0 - 1] |
currentRatioTTM | 4.37 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 2.54 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 0.962 | 1.500 | 5.77 | 8.65 | [0.2 - 2] |
debtRatioTTM | 0.203 | -1.500 | 6.61 | -9.91 | [0 - 0.6] |
interestCoverageTTM | 20.76 | 1.000 | 3.42 | 3.42 | [3 - 30] |
operatingCashFlowPerShareTTM | 1.755 | 2.00 | 9.42 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 1.431 | 2.00 | 9.28 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.283 | -1.500 | 8.87 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.671 | 1.000 | 2.15 | 2.15 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.235 | 1.000 | 7.31 | 7.31 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.497 | 1.000 | 8.35 | 8.35 | [0.2 - 2] |
assetTurnoverTTM | 0.419 | 0.800 | -0.538 | -0.430 | [0.5 - 2] |
Total Score | 11.84 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 45.02 | 1.000 | 5.55 | 0 | [1 - 100] |
returnOnEquityTTM | 0.115 | 2.50 | 9.90 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 1.431 | 2.00 | 9.52 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0.500 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 1.755 | 2.00 | 9.42 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.225 | 1.500 | 7.75 | -7.75 | [0 - 1] |
pegRatioTTM | 0.335 | 1.500 | -1.100 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.241 | 1.000 | 6.46 | 0 | [0.1 - 0.5] |
Total Score | 6.04 |
Bio-Techne Corp
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。